AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Recent HIV/AIDS News from NIAID and FDA
News from NIAID
June 2, 2014: Scientists Uncover Features of Antibody-Producing Cells in People Infected with HIV
"By analyzing the blood of almost 100 treated and untreated HIV-infected volunteers, a team of scientists has identified previously unknown characteristics of B cells in the context of HIV infection. B cells are the immune system cells that make antibodies to HIV and other pathogens. The findings augment the current understanding of how HIV disease develops and have implications for the timing of treatment."
News from FDA
May 30, 2014: June 17, Workshop on HIV Cure Resear...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 6, 2014 Category: Infectious Diseases Source Type: news
June 8 is Caribbean-American HIV/AIDS Awareness Day
On June 8, AIDSinfo joins the nation in observing Caribbean-American HIV/AIDS Awareness Day. This day serves to raise awareness of HIV/AIDS in the Caribbean, a region disproportionately affected by this disease. According to the U.S Agency for International Development (USAID), outside of sub-Saharan Africa, the Caribbean region has the highest HIV prevalence in the world. In addition to raising awareness, the purpose of this day is to provide information and resources about HIV/AIDS to Caribbean Americans.
Explore our Caribbean-American HIV/AIDS Awareness Day webpage [en español] to learn more about the observance...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 6, 2014 Category: Infectious Diseases Source Type: news
National Library of Medicine Announces Solicitation of Quotations for the 2014 HIV/AIDS Community Information Outreach Projects
The National Library of Medicine (NLM) is pleased to announce the solicitation of quotations from organizations and libraries to design and conduct projects that will improve access to HIV/AIDS-related health information for patients, the affected community, and their caregivers.
Projects must involve one or more of the following information access categories:
Information retrieval;
Skills development;
Resource development; and/or
Equipment acquisition.
Emphasis is placed upon the following types of organizations or arrangements for developing these programs:
Community-based orga...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 6, 2014 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from CDC, NIH, and FDA
News from CDC
May 21, 2014: New CDC Campaign Inspires Life-Saving Conversations About HIV
“The Centers for Disease Control and Prevention today launched Start Talking. Stop HIV., a new national communication campaign encouraging gay and bisexual men to talk openly with their sexual partners about HIV risk and prevention strategies.”
News from NIH
May 19, 2014: 2014 Avant-Garde Awards Focus on Strengthening the Immune System
“With proposals ranging from enhancing the immune system’s ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists h...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 23, 2014 Category: Infectious Diseases Source Type: news
CDC Announces Release of New Clinical Practice Guidelines for PrEP Use
New guidelines developed by CDC in partnership with other federal health agencies, public health experts, and community leaders update recommendations on the use of pre-exposure prophylaxis (PrEP) for the prevention of HIV infection in adults in the United States. The guidelines recommend that health care providers consider PrEP for people who are at substantial risk for HIV infection.
The new guidelines include recommended indications for PrEP use; information on Truvada (emtricitabine/tenofovir disoproxil fumarate), the FDA-approved drug for use as PrEP in combination with safer sex practices; and advice for providers o...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 23, 2014 Category: Infectious Diseases Source Type: news
AIDSinfo and infoSIDA Websites Now Optimized for Display on Mobile Devices
AIDSinfo recently updated the AIDSinfo and infoSIDA websites, and they are now automatically optimized for display across all devices—desktop computers, tablets, and smartphones. Visitors to the AIDSinfo and infoSIDA websites will now be able to access all of the website content on any device they are using.
We decided to create a responsive design website—a site that automatically adjusts to any device—because of a shift in ways people are accessing the Internet. Between 2010 and 2014, mobile traffic to the AIDSinfo website increased 10-fold, and almost 90% of health care providers surveyed on the AIDS...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 23, 2014 Category: Infectious Diseases Source Type: news
May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day
. The annual observance was founded by the Banyan Tree Project, with support from the Centers for Disease Control and Prevention (CDC). The goal of the project is to stop HIV/AIDS-related stigma in Asian and Pacific Islander communities. According to the Banyan Tree Project, “… this type of discrimination prevents A&PIs [Asians and Pacific Islanders] from getting tested for HIV and from getting health care and other services they need to stay healthy.”
Explore our National Asian and Pacific Islander HIV/AIDS Awareness Day webpage [en español] to learn more about the observance and find relate...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 9, 2014 Category: Infectious Diseases Source Type: news
May 18 is HIV Vaccine Awareness Day
HIV Vaccine Awareness Day is observed each year on May 18. The day serves as an occasion to recognize and thank the many volunteers, community members, health professionals, and scientists working together toward finding an HIV vaccine. This day also serves to highlight the importance of HIV vaccine research.
We invite you to explore our HIV Vaccine Awareness Day webpage [en español] to learn more about this observance and HIV vaccine research that is currently in progress. (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 9, 2014 Category: Infectious Diseases Source Type: news
FDA Updates Rilpivirine (Edurant) Labeling
“On May 1, 2014, FDA approved changes to the Edurant (rilpivirine) label to include drug-drug interaction with rilpivirine and metformin and rilpivirine and rifabutin.
“Under section 2 Dosage and Administration:
“Rifabutin Co-administration: For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) once daily, taken with a meal. When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily, taken with a meal.
“Rilpivirine did not have a clinically significant effect on the pharmacoki...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 9, 2014 Category: Infectious Diseases Source Type: news
Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Released
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Key additions and revisions to the guidelines include:
Addition of “Cost Considerations and Antiretroviral Therapy,” a new section that discusses strategies to contain costs without compromising treatment effectiveness.
Changes to recommendations on the frequency of CD4 count monitoring, including a table that outlines the updated recommendations.
Change in classification of recommendations for initial t...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 1, 2014 Category: Infectious Diseases Source Type: news
Updated Fact Sheets Available From CDC
The Centers for Disease Control and Prevention (CDC) recently updated the following three fact sheets:
HIV and Viral Hepatitis
This fact sheet describes the impact of viral hepatitis on people with HIV and provides information on viral hepatitis transmission, prevention, and treatment.
HIV Among Youth
This fact sheet provides information and statistics on HIV and AIDS diagnoses among youth in the United States. HIV prevention challenges specific to youth are also discussed.
HIV/AIDS Among American Indians and Alaska Natives
This fact sheet provides inf...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 25, 2014 Category: Infectious Diseases Source Type: news
“Drugs That Fight HIV-1” Brochure Recently Updated
The National Institute of Allergy and Infectious Diseases (NIAID) recently updated the “Drugs That Fight HIV-1” brochure, which features images of FDA-approved antiretroviral medications, grouped by drug class and identified by both generic and brand names. The brochure is available in both English and Spanish. It can be a helpful tool for health care professionals to use when discussing HIV treatment with patients.
The brochure can be found in the HIV/AIDS Images section of Health Topics on our website. Contact our health information specialists by phone (1-800-448-0440) or e-mail (ContactUs@aidsinfo.nih...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 25, 2014 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from NIAID
April 3, 2014: Future HIV Vaccine Research Must Consider Both Protective Immune Responses and Those That Might Increase Susceptibility to Infection
“Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility to HIV infection. In a new perspectives article appearing in the journal Science, HIV research leaders from NIAID (Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D.) and its grantees at Emory University (Eric Hunter, Ph.D.) and ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
FDA Updates Darunavir (Prezista) Labeling
“On April 7, 2014, FDA approved new changes to the Prezista (darunavir) label to update the following sections:
“WARNING AND PRECAUTIONS, Severe Skin Reactions, ADVERSE REACTIONS, Postmarketing Experience, and PATIENT COUNSELING INFORMATION sections of the labeling were updated with information regarding rash with eosinophilia and systemic symptoms.
“DRUG INTERACTIONS, Established and Other Potentially Significant Drug Interaction and CLINICAL PHARMACOLOGY, Table 15 subsections of the labeling were updated with information regarding dolutegravir. …
“CLINICAL PHARMACOLOGY, M...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
FDA Updates Raltegravir (Isentress) Labeling
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir.
“In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.”
The revised label is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Raltegravir (Isentress) patient fact sheet (Source: AIDSinfo At-a-Glance: Offering Information on HIV/A...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
